Anixa Biosciences to Host Conference Call to Provide Update on Programs
Anixa Biosciences, Inc. (NASDAQ: ANIX) will host a conference call on November 2, 2020, at 1:30 p.m. Pacific / 4:30 p.m. Eastern. CEO Dr. Amit Kumar will discuss key developments, including the upcoming Investigational New Drug (IND) application for a breast cancer vaccine in partnership with the Cleveland Clinic, progress on CAR-T therapy for ovarian cancer with Moffitt Cancer Center, and updates on COVID-19 therapy. Investors can join via phone at (877) 876-9174 (Conference ID: Anixa) or through a webcast on the company’s website.
- None.
- None.
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern.
Dr. Amit Kumar, Anixa's Chief Executive Officer, will provide an update on the status of the Company's programs, including the impending filing of an Investigational New Drug (IND) application for its breast cancer vaccine, being developed with the Cleveland Clinic, the progress with its CAR-T treatment for ovarian cancer, being developed with the Moffitt Cancer Center, and the latest discoveries with its Covid-19 therapy.
Conference Call Information:
Interested participants and investors may access the conference call by dialing:
- (877) 876-9174
- Conference ID: Anixa
An audio webcast will be accessible via the Investors section of the Anixa website at https://ir.anixa.com/events. An archive of the webcast will remain available for 30 days after the call.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC). Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, the timing of the impending filing of an IND application for the breast cancer vaccine we are working on with the Cleveland Clinic, as well as those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-host-conference-call-to-provide-update-on-programs-301160333.html
SOURCE Anixa Biosciences, Inc.
FAQ
When will Anixa Biosciences hold its conference call?
What will be discussed in the Anixa conference call?
How can I access the Anixa conference call?
Who is leading the Anixa conference call?
What is the focus of Anixa Biosciences?
